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ABSTRACT 
It has previously been postulated that the therapeutic effect of antidepressants, particularly 
selective serotonin re-uptake inhibitors (SSRIs), is mediated by a down-regulation of 
somatodendritic (presynaptic) 5-HT1A autoreceptors with chronic treatment.  Animal 
studies have revealed that repeated administration of corticosteroids similarly down-
regulate this receptor.  However, it has previously been difficult to explore if this receptor 
is similarly modulated in man in vivo.  The objective of this study was to explore the effect 
of repeated administration of cortisol to healthy volunteers utilising a novel putative index 
of somatodendritic 5-HT1A autoreceptor function.  This method involves the administration 
of the 5-HT1A agonist buspirone and observing the subsequent negative shift in the 
frequency spectrum of the electroencephalogram (EEG).  Healthy male volunteers were 
treated with cortisol 20 mg, or placebo, orally twice daily for seven days in a double-blind 
random-order cross-over study.  After each treatment period volunteers were administered 
buspirone 30 mg orally prior to EEG recordings.  Following a week's treatment with 
placebo, buspirone led to a negative shift in the EEG frequency spectrum as previously 
reported.  However following treatment with cortisol, the effect of buspirone was 
significantly attenuated.  This is consistent with corticosteroids having a similar effect on 
somatodendritic 5-HT1A autoreceptors in man as seen in rodents. 
 
Key words:  Cortisol, EEG, 5-HT1A receptors, buspirone 
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INTRODUCTION 
Corticosteroid hormones (cortisol in man and corticosterone in rodents) mediate the body’s 
response to physical and psychological stressors.  The actions of these hormones on 
neurotransmitter systems in the brain may impact on cognitive performance and mental 
health.  Indeed it has long been postulated that cortisol plays an aetiological role in mood 
disorders (Dinan, 1994; McAllister-Williams et al., 1998).  In animal studies 
corticosteroids have been shown to have several effects on elements of the central 5-HT 
neurotransmitter system including attenuation of 5-HT1A receptor function.  5-HT1A 
receptors are located both as autoreceptors on the somata and dendrites of serotonin 
containing neurones in the raphe nuclei and postsynaptically on cells throughout the 
forebrain (Burnet et al., 1995; Azmitia et al., 1996; Pasqualetti et al., 1996).  Activation of 
somatodendritic 5-HT1A autoreceptors plays a key role in determining the activity of the 
entire serotonergic system both in terms of firing activity (Aghajanian and VanderMaelen, 
1982; McAllister-Williams and Kelly, 1995) and the release of 5-HT in terminal areas 
(Sharp et al., 1993).  With this in mind, it is of particular interest that repeated 
administration of corticosteroids has been consistently shown to attenuate somatodendritic 
5-HT1A receptor function in rodent studies (Young et al., 1992; Young et al., 1994a; Laaris 
et al., 1995; McAllister-Williams et al., 2001; Man et al., 2002; McAllister-Williams et al., 
1999; Fairchild et al., 2003).  This effect is also seen with endogenous increases in 
circulating corticosteroids in response to stress (Laaris et al., 1997).   
 
The examination of brain 5-HT receptor function in man in vivo is difficult.  
Neuroendocrine challenge test have been widely used to probe postsynaptic 5-HT1A and 
5-HT2 receptors in the hypothalamus and pituitary.  The hypothermic response to 5-HT1A 
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receptor agonists can also be used as an index of 5-HT1A receptor function and it has been 
shown that repeated cortisol administration to healthy volunteers attenuates the 
hypothermic response to buspirone (Young et al., 1994b) in line with findings in rodents.  
However, there is continuing controversy concerning the somatodendritic or postsynaptic 
location of receptors mediating this effect (Blier et al., 2002).  An alternative method of 
assessing the functional status of the somatodendritic 5-HT1A receptor in man in vivo may 
be the effect of the 5-HT1A receptor agonist buspirone on the EEG frequency spectrum 
(McAllister-Williams and Massey, 2003). 
 
There are consistent findings that buspirone administration to healthy humans leads to 
negative shift of the awake EEG frequency spectrum in man (due to an increase in theta 
and decrease in alpha activity) (Murasaki et al., 1989; Barbanoj et al., 1994; Holland et al., 
1994; Anderer et al., 2000).  Although buspirone is a relatively non-selective drug, and its 
systemic administration makes the localization of effects difficult, several pieces of 
evidence indicate that this negative shift may be mediated by somatodendritic 5-HT1A 
receptors.  Firstly, the EEG frequency effects are mimicked by other more selective 
5-HT1A partial agonists in man (Saito et al., 1993; Anderer et al., 2000) and is seen in 
animals following administration of buspirone as well as the highly selective full 5-HT1A 
receptor agonist 8-OH-DPAT (Bogdanov and Bogdanov, 1994).  Secondly, source 
localization of the effect of buspirone using low resolution electromagnetic tomographic 
analysis (LORETA) demonstrates a significant increase in theta EEG activity in the 
hippocampus as well as neighbouring cortical areas (Anderer et al., 2000).  Hippocampal 
theta activity is well known to be under ascending serotonergic control (Vertes, 1982).  
Animal studies using local application of 8-OH-DPAT into the raphe have indicated that 
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activation of somatodendritic 5-HT1A receptors causes a decrease in hippocampal theta 
(Vertes et al., 1994; Nitz and McNaughton, 1999), an effect blocked by 5-HT1A antagonists 
(Marrosu et al., 1996).  Thirdly, a somatodendritic location for a 5-HT1A receptor mediated 
negative shift in the EEG frequency spectrum in man is also inferred from findings of 
acute administration of SSRIs causing such a shift (Saletu et al., 1986) and that pindolol 
mimics, rather than blocks, the effect of buspirone on the awake EEG (McAllister-
Williams and Massey, 2003).  Following acute administration, SSRIs increase 
concentrations of 5-HT in the raphe nuclei leading to somatodendritic 5-HT1A activation 
(Bel and Artigas, 1992); pindolol acts as a 5-HT1A antagonist at postsynaptic receptors but 
a partial agonist at somatodendritic receptors (Clifford et al., 1998).  Taken together, these 
data support the hypothesis that the effect of buspirone on the EEG frequency spectrum is 
a potential index of somatodendritic 5-HT1A receptor function. 
 
The aim of this study was to examine whether repeated corticosteroid administration 
attenuates somatodendritic 5-HT1A receptor function in man.  The a priori hypothesis was 
that cortisol administration would lead to an attenuation of somatodendritic 5-HT1A 
receptor function as indexed by a reduction in the buspirone induced negative shift in the 
EEG frequency spectrum. 
 
METHODS AND MATERIALS 
 
Subjects 
Twenty four healthy male subjects aged between 18 and 33 years (mean ± SD: 24 ± 3.8) 
gave written informed consent to participate in the study, which had been approved by the 
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Newcastle and North Tyneside Local Research Ethics Committee in accordance with the 
ethical standards laid down in the 1964 Declaration of Helsinki.  All subjects were free of 
significant past or present physical illness and had received no medication for at least 2 
months prior to their participation.  They were screened to exclude significant current, past 
or family history of psychiatric illness.  In addition, the volunteers were all right handed, 
within a weight range of 70-100 kg, and had not experienced previous adverse reactions to 
steroids. 
 
Experimental procedure and medication 
Subjects were tested on two separate occasions at least three weeks apart to minimise any 
potential carry over effects of cortisol treatment.  Prior to each testing session they were 
treated with hydrocortisone 20mg twice daily or placebo in a double-blind cross-over, 
random, balanced-order fashion over the course of the preceding week.  Treatment started 
in the evening of "day 1" at approximately 2100 hours and finished with a 14th dose at 
approximately 0800 hours on "day 8".  Following their first void of urine on day 7, 
subjects collected their urine for 24 hours, up to and including their first void on day 8. 
 
Subjects attended the research laboratory at 1200 hours and were given a light lunch and a 
drink prior to testing.  They subsequently completed a short computer-based cognitive task 
(to assess executive function and published elsewhere (McAllister-Williams et al., 2002)).  
Volunteers were given free access to drinking water but were otherwise fasted during the 
experiment.  At baseline (approximately 1300 hours) a blood sample was obtained, a 
number of visual analogue scales (VASs) completed, and EEG recorded with subjects 
sitting in front of a computer monitor with a fixation point displayed in the centre.  
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Following baseline measurements, buspirone 30mg was administered orally.  Three further 
sets of measurements (VAS and EEG recording) were conducted at half hourly intervals 
for 90 minutes (t = 30, 60 and 90 min). 
 
EEG recordings and analysis 
EEG recordings and analysis were as previously described (McAllister-Williams and 
Massey, 2003).  Briefly, EEG was recorded from 29 silver/silver chloride electrodes 
positioned on the scalp using an elasticated cap (Easy Caps, Germany) and sited in 
accordance with the International 10-20 system (American Electroencephalographic 
Society, 1994).  Further electrodes were placed on the right and left mastoid processes.  All 
channels were recorded relative to the left mastoid.  Vertical electro-occulograms (VEOG) 
was recorded between electrodes placed on the nazion and electrodes below the centre of 
each eye.  Horizontal EOG (HEOG) was recorded between electrodes placed on the outer 
canthus of the eyes.  EEG and EOG were filtered with a bandpass of 0.1 − 100 Hz and 
sampled at a rate of 400 points per second.  At each recording time point, subjects were 
instructed to keep their eyes open and to maintain their gaze on the fixation point (a red 
cross) displayed on a computer monitor, remain still and relaxed, and to keep their minds 
as blank as possible for three 3 minute periods interspersed with 30 second rest intervals 
between.  Ten minutes of continuous EEG was acquired during this period. 
 
A standardised EEG analysis procedure was followed using Neuroscan Scan 4.1 software 
(Neurosoft Inc. USA).  This included blink-correction (Semlitsch et al., 1986) and a 
principle component analysis (PCA) to remove any visible ECG artefact.  Data was 
algebraically re-referenced to represent recordings from average mastoid reference and 
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epoched into segments 10.24 seconds long.  Any epoch in which any channel, except 
VEOG, had a voltage deflection greater than ±75 µV was excluded.  Remaining epochs 
underwent Fast Fourier Transformation (FFT) and were averaged together.  The precision 
of the FFT was 0.098 Hz.  Potential shifts in the EEG frequency spectrum were assessed 
by calculating the centroid frequency between 6 and 10.5 Hz (Anderer et al., 1993; 
McAllister-Williams and Massey, 2003).  This standardised analysis protocol is associated 
with extremely high test-retest reliability (McAllister-Williams and Massey, 2003). 
 
Visual Analogue Scales 
Visual analogue scales (VASs) consisted of 100 mm scales on which subjects rated 
"depression", "drowsiness", "restlessness", "nausea" and "lightheadedness", with "the most 
severe possible" at one end and "not at all" at the other. 
 
Cortisol Assays 
Baseline blood samples were taken into EDTA tubes, centrifuged at 3,000 rpm for 10 
minutes and plasma removed and stored at -20°C.  Samples were analysed for cortisol 
using radioimmunoassay kits (Immuno Diagnostic Systems Ltd, Boldon, Tyne and Wear, 
UK).  Intra- and inter-assay coefficients of variation for the assay were 8.1% and 8.5% 
respectively.  Subjects collected their 24 hr urine samples into 2 litre bottles containing 5g 
of boric acid.  The cortisol level of an aliquot of the urine was assayed using a similar 
radioimmunoassay to that used for the plasma samples.  The intra- and inter-assay 
coefficients of variation were 14.0% and 12.8% respectively. 
 
Statistical analysis 
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SPSS (version 11.0, Chicago, Illinois) was used throughout.  For the analysis of the shift in 
EEG frequency spectrum, the change in centroid frequency, calculated between 6 and 10.5 
Hz, over the 90 minutes following buspirone administration was quantified as an area 
under the curve (AUC) at t = 30, 60 and 90 minutes relative to that at t = 0 minutes (i.e. 
subtraction of the baseline extrapolated from t0) using the trapezoid method.  The primary 
outcome measure was the AUC for data recorded at the CZ electrode only (in line with the 
published methodology (McAllister-Williams and Massey, 2003).  The effect of pre-
treatment with cortisol versus placebo on the AUC measurement was compared using a 
two-tailed paired t-test.  ANOVA was also performed as a secondary outcome measure on 
the change in centroid time series data with within subject factors of “treatment” (cortisol 
vs placebo) and “time” (30, 60 and 90 min.).  The AUC data from all 29 active electrode 
sites was analysed using a repeated measures ANOVA employed within subject factors of 
“treatment” and “electrode site”.  VAS data was analysed with within subject factors of 
“treatment” and “time”.  In addition, possible correlations between 24 hour urinary cortisol 
concentrations and the EEG responses to buspirone administration were assessed using the 
Spearman’s rank correlation coefficient. 
 
The Kolmogorov-Smirnov test was applied to all data.  This revealed no significant 
departure from normality of the centroid frequency, AUC values, or urinary free cortisol 
concentrations.  VAS data did however deviate from normality as did log transformed 
values, though less so.  All ANOVA analyses incorporated the Greenhouse-Geisser 
correction for inhomogeneity of covariance, with F ratios reported with corrected degrees 
of freedom.  All values are quoted as mean ± SD. 
 
 McAllister-Williams et al.     Cortisol and somatodendritic 5-HT1A receptors 
 
 
 
 
Page 10 of 24 
 
C:\Documents and Settings\nlmm3\Desktop\cortisol_5-HT1A 20_01_07.doc 
Last saved on 04/08/2008 14:21:00 
 
RESULTS 
 
Subjects 
Of the 24 subjects recruited to the study, four had to withdraw during the first visit due to 
intolerance of the side effects of buspirone (three with lightheadedness or nausea and one 
vomiting).  One subject with extremely low 24-hour urinary free cortisol levels following 
cortisol pre-treatment and was excluded from the analysis (see below for details).  Data 
from a further two subjects were excluded due to their EEG being heavily contaminated 
with movement artifacts.  Data for the remaining seventeen subjects are presented. 
 
Subjects scored a mean (± SD) of 0.1 ± 0.3 on the Hamilton Depression Rating Scale (18-
item; HDRS; range: 0-1) and 0.9 ± 1.3 on the Beck Depression Inventory (BDI; range: 0-
4).  Mean full scale IQ was estimated at 114 ± 6.5 using the National Adult Reading Test 
(NART; range: 100-123).  Subjects weighed 82.3 ± 9.2 kg with a body mass index of 25.0 
± 2.5 (range 22.0 - 30.3). 
 
Baseline plasma and 24 hour urinary cortisol concentrations 
Urinary free cortisol concentrations were significantly increased following cortisol pre-
treatment relative to placebo (cortisol: 556 ± 187 nmol/l; placebo: 240 ± 82 nmol/l; t (16) = 
-7.52, p < 0.001).  The subject that was excluded from the analysis on the basis of their 
urinary cortisol concentration had a level of 61 nmol/l, which was more than two standard 
deviations below the group mean following cortisol pre-treatment, and substantially lower 
than the value observed for the same subject following placebo pre-treatment (260 
 McAllister-Williams et al.     Cortisol and somatodendritic 5-HT1A receptors 
 
 
 
 
Page 11 of 24 
 
C:\Documents and Settings\nlmm3\Desktop\cortisol_5-HT1A 20_01_07.doc 
Last saved on 04/08/2008 14:21:00 
 
nmol/L).  This was the only subject who did not show an increase between the placebo and 
cortisol arms of the study (figure 1). 
 
Figure 1 near here 
 
Baseline plasma cortisol concentrations prior to the administration of buspirone (at 
approximately 1300 hours) were not statistically different (placebo: 306 ± 23 nmol/L; 
cortisol: 348 ± 53 nmol/L, t(13) = -0.72, p > 0.1).   
 
Effect of cortisol pre-treatment on buspirone EEG effects 
 
Figure 2 near here 
 
Following placebo pre-treatment buspirone administration caused a decrease in the 
centroid frequency.  When subjects were pre-treated with cortisol this effect of buspirone 
was attenuated (figure 2).  The a priori defined primary outcome measure, the AUC for the 
centroid frequency for t = 30, 60 and 90 minutes relative to the value at t = 0 minutes, was 
significantly less negative following cortisol compared to placebo pre-treatment (-0.37 ± 
14.85 vs -7.34 ± 15.93 Hz.min; t(16) = -2.14, p < 0.05).  The baseline centroid frequency 
values at t = 0 minutes recorded at Cz did not significantly differ between the two 
treatment arms (8.19 ± 0.31 Hz vs 8.11 ± 0.35 Hz, placebo vs cortisol;  t(16) = 1.79, p > 
0.05).  Repeated measures ANOVA of the change in centroid frequency from t = 0 at t = 
30, 60 and 90 minutes revealed a significant main effect of cortisol versus placebo pre-
treatment (F(1,16) = 4.52, p < 0.05) but there was no treatment by time interaction.  To 
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explore if the decrease in AUC following cortisol pre-treatment simply reflected an effect 
of cortisol on the baseline centroid frequency rather than an effect of cortisol on the 
buspirone EEG response, the correlation between baseline centroid frequency and AUCs 
was examined (figure 3).  This revealed no significant correlation between the baseline 
centroid frequency and AUC for the change following buspirone administration recorded 
after either placebo or cortisol pre-treatment, or when all data was combined. 
 
Figure 3 near here 
 
The topography of the effect of cortisol pre-treatment on the baseline centroid frequency 
was examined by conducting repeated measures ANOVA on the data from all 29 electrode 
sites.  This revealed a trend for a main effect of cortisol pre-treatment (F(1,16 = 4.14, p < 
0.1) but no treatment by site interaction.  Likewise ANOVA of AUC data across the head 
revealed a trend for an effect of cortisol pre-treatment (F(1,16) = 3.52, p <0.1) but again no 
treatment by site interaction.  This suggests the effects of cortisol pre-treatment do not 
modulate the topography of the buspirone EEG effects. 
 
Effect of cortisol pre-treatment on buspirone induced subjective effects 
Repeated measures ANOVA of the log transformed data from individual VAS scales found 
no effect of pre-treatment, time or pre-treatment by time interaction for the "depressed", 
"drowsy" and "restless" scales, indicating a lack of effect of buspirone and cortisol pre-
treatment.  However, there was a significant effect of time for both the "nausea" and 
"lightheadedness" scales (F(2.1,31.7) = 9.10, p < 0.001 and F(2.4,36.3) = 5.27, p < 0.005 
respectively) due to buspirone increasing these symptoms.  Nevertheless, once again there 
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was no effect of cortisol pre-treatment or pre-treatment by time interaction for either of 
these two scales.   
 
DISCUSSION 
The aim of the present study was to examine the effect of repeated cortisol administration 
on somatodendritic 5-HT1A receptor function in healthy volunteers. Healthy young men 
were treated with cortisol or placebo in a cross over design and the EEG response 
(frequency shift) to buspirone was used as a marker of somatodendritic 5-HT1A receptor 
function.  We found that buspirone caused a negative shift in EEG frequency spectrum and 
that cortisol treatment attenuated this effect.  The data are consistent with the a priori 
hypothesis that repeated administration of cortisol decreases somatodendritic 5-HT1A 
receptor function and are consistent with data from rodent studies showing similar effects. 
 
The cortisol treatment paradigm 
In exploring whether alterations in corticosteroid concentrations may have an effect on 
somatodendritic 5-HT1A function in man, clearly the choice of cortisol administration 
paradigm is important.  Here we used repeated administration for one week and ensured 
that testing was performed long enough after the last dose so that subjects were 
normocortisolaemic.  We used 24h urinary free cortisol as a measure of the ability of 
cortisol administration to raise circulating cortisol.  Previous studies (Young et al., 1999; 
McAllister-Williams and Rugg, 2002) using this paradigm of administration found 24h 
urinary cortisol was markedly elevated at the end of the cortisol arm of treatment relative 
to the placebo arm.  We were also able to use this measure as an indicator of subject 
compliance and identified one individual who apparently had not been taking his 
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medication as directed.  Plasma cortisol concentration immediately before testing did not 
differ between the two arms.  This reflects the rapid clearance of cortisol between the time 
of the last dose (approximately 0800 hours) and the time of the first blood sample 
(approximately 1300 hours).  The finding confirms that subjects were normocortisolaemic 
at the time of testing with no evidence of adrenal suppression following the cortisol pre-
treatment.  This suggests that the effect seen in this study does not relate to differences in 
cortisol concentrations at the time of assessing somatodendritic 5-HT1A receptor function, 
but rather the repeated increases over the preceding seven days. 
 
The Buspirone EEG Response 
In previous pilot studies as well as a published report of the effects of buspirone on the 
EEG frequency spectrum (McAllister-Williams and Massey, 2003) we have found that the 
peak effect is seen either 30 or 60 minutes post oral administration of buspirone, with the 
effects waning by 90 minutes.  Variation is seen between individuals presumably due to 
variations in rates of oral absorption.  Since each EEG recording requires 10 minutes of 
data to obtain the precision in the FFT the number of data points obtainable from subjects 
is limited.  The primary analysis focused on the AUC for the three data points post 
buspirone administration to take into account inter-subject variation in time to maximal 
effect.  The focus on a single electrode (Cz) increases the statistical power of the study.  A 
priori it was determined that 16 subjects provided an 80% chance of detecting a 50% 
decrease with cortisol pre-treatment in the negative shift in EEG frequency at Cz with 
buspirone, utilising a within subject methodology. 
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Although the present study involved just two treatment arms and no placebo control for the 
effect of buspirone, we have previously observed that placebo/time alone has little effect 
on the EEG frequency spectrum (McAllister-Williams and Massey, 2003).  Hence we are 
confident in ascribing the shift in frequency spectrum to the effect of buspirone over time 
rather than to time alone.  Although the effect of buspirone in the current study was of 
smaller magnitude than we have previously reported (-7.34 Hz.min cf -14.73 Hz.min), the 
within subject design of the current study ensured sufficient statistical power to detect a 
significant effect of cortisol on the buspirone effect on the EEG frequency spectrum.  
Indeed it was noted that there was a high degree of correlation between individual’s 
baseline centroid frequencies (r = 0.79, p < 0.001) between the placebo and cortisol 
conditions, demonstrating minimal intra-subject variation over time and the robustness of 
the EEG measures. 
 
The Effect of Cortisol on the Buspirone EEG Response 
Repeated cortisol treatment resulted in an attenuation of the effect of buspirone on its 
negative shift in the EEG frequency spectrum.  The effect of cortisol was observed over the 
whole time course of the EEG recording as evidenced by the significant decrease in AUC 
and the significant main effect in the time course ANOVA.  The effect of cortisol was also 
observed over the whole scalp surface with no electrode by treatment interaction being 
observed.  We have previously shown that the effect of buspirone is greatest at Cz but is 
apparent in all electrode locations. 
 
Cortisol pre-treatment was associated with a non-significant decrease in baseline EEG 
centroid frequencies between 6 and 10.5 Hz, prior to the administration of buspirone.  It is 
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possible that this could compromise the conclusion that cortisol pre-treatment led to a 
reduction in the shift in frequency spectrum following buspirone administration (as 
measured with the AUC relative to the baseline) due to a "floor effect".  However, there 
was no correlation between baseline centroid frequencies and AUC values following 
placebo pre-treatment, cortisol pre-treatment, or when all the data was combined (see 
figure 3) as one might have expected if this was the case.  It is likely that there are multiple 
transmitter systems that determine the level of the baseline centroid frequency beyond 
serotonergic ones.  As a result, a down-regulation of somatodendritic 5-HT1A receptors 
following cortisol pre-treatment, may have little effect on the resting EEG frequencies 
unless there is activation of the system, as occurs with buspirone administration. 
 
The finding that cortisol pre-treatment has no effect on the subjective symptoms induced 
by buspirone is consistent with previous data (Young et al., 1994b; Porter et al., 2002).  It 
suggests that any effect of cortisol on the buspirone EEG response is not secondary to 
subjective symptoms experienced by the volunteers.  Interestingly although, buspirone 
caused some nausea and lightheadedness as previously reported, these effects were 
unaltered by the cortisol pre-treatment.  These data are important in providing indirect 
evidence that the attenuation of the EEG effect was not simply due to a cortisol-induced 
change in the pharmacokinetics of buspirone. 
 
Implications of findings 
A fundamental question is why some individuals become depressed when exposed to life 
stress, whereas others remain well.  Serotonergic central pathways have been argued to be 
fundamental to mechanisms of resilience to stress (Deakin and Graeff, 1991).  Effects of 
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cortisol on serotonergic function may be the means by which environmental factors are 
transduced to a change in serotonergic function.  The findings of this study, supported by 
numerous animal investigations, suggest that repeated administration of cortisol attenuates 
somatodendritic 5-HT1A autoreceptor function, an effect similar to that seen with 
antidepressants in pre-clinical studies.  As such it is inviting to speculate that this cortisol-
5-HT interaction might be importance in mechanisms of resilience in man.  Further 
research is required to delineate the dynamic nature of the effects of alterations in plasma 
cortisol on somatodendritic 5-HT1A autoreceptor function, and if such interactions are 
dysfunctional in subjects at risk of depression, it will be important to investigate whether a 
dysfunctional interaction predicts the development of depression in response to stress. 
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FIGURE LEGENDS 
Figure 1.  Urinary free cortisol concentrations.  24 hour urinary free cortisol 
concentrations of subjects after placebo and cortisol pre-treatment.  Individual data points 
for all subjects, including J017 (indicated by solid circle data point) who was excluded 
from all analyses as described in the text.  
 
Figure 2.  A. Time course of the effect of buspirone on the EEG centroid frequency 
measured between 6 and 10.5 Hz at the Cz electrode site following placebo and cortisol 
pre-treatment.  Baseline, prior to buspirone administration, is indicated by time = 0 
minutes.  Data plotted as change from baseline.  B.  Bar graph of the area under the curve 
(AUC) for the change in centroid frequency at CZ following placebo and cortisol pre-
treatment. 
 
Figure 3.  Correlation between baseline centroid frequency between 6 and 10.5 Hz and the 
AUC for the change in baseline following treatment with buspirone.  Data plotted for 
individual subjects separately for placebo and cortisol pre-treatments.  Linear regression 
lines plotted (GraphPad Prism V3.0) for each.  No significant correlation found. 
 McAllister-Williams et al.     Cortisol and somatodendritic 5-HT1A receptors 
 
 
 
 
Page 22 of 24 
 
C:\Documents and Settings\nlmm3\Desktop\cortisol_5-HT1A 20_01_07.doc 
Last saved on 04/08/2008 14:21:00 
 
Figure 1 
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